Stefan Leucht
#144,870
Most Influential Person Across History
Researcher ORCID ID = 0000-0002-4934-4352
Stefan Leucht's AcademicInfluence.com Rankings
Stefan Leuchtcomputer-science Degrees
Computer Science
#4137
Historical Rank
Machine Learning
#634
Historical Rank
Artificial Intelligence
#840
Historical Rank
Database
#1244
Historical Rank
Download Badge
Computer Science
Why Is Stefan Leucht Influential?
(Suggest an Edit or Addition)Stefan Leucht's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis (2013) (1929)
- Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (2011) (1903)
- Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis (2009) (1714)
- Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis (2018) (1627)
- What does the PANSS mean? (2005) (991)
- Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials (1999) (795)
- Clinical implications of Brief Psychiatric Rating Scale scores. (2005) (710)
- Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis (2012) (702)
- Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. (2004) (641)
- Physical illness and schizophrenia: a review of the literature (2007) (620)
- Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level (2011) (620)
- Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis (2010) (612)
- The effect of family interventions on relapse and rehospitalization in schizophrenia--a meta-analysis. (2015) (596)
- Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis (2019) (582)
- New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis (2003) (524)
- A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. (2009) (478)
- Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. (2003) (456)
- How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials (2009) (439)
- Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis (2016) (430)
- The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. (2003) (414)
- Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. (2006) (406)
- Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. (2009) (373)
- Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses (2012) (343)
- Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. (2014) (341)
- Dose Equivalents for Antipsychotic Drugs: The DDD Method. (2016) (339)
- Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. (2008) (322)
- Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. (2017) (305)
- Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials (2011) (299)
- Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. (2014) (288)
- Standardized remission criteria in schizophrenia (2006) (282)
- Shared decision making for in‐patients with schizophrenia (2006) (273)
- Linking the PANSS, BPRS, and CGI: Clinical Implications (2006) (267)
- Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. (2002) (265)
- Dose equivalents for second-generation antipsychotics: the minimum effective dose method. (2014) (263)
- Clozapine versus other atypical antipsychotics for schizophrenia. (2010) (262)
- Maintenance treatment with antipsychotic drugs for schizophrenia. (2012) (252)
- Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. (2010) (244)
- Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. (2014) (244)
- Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. (2014) (239)
- Do patients with schizophrenia wish to be involved in decisions about their medical treatment? (2005) (234)
- Efficacy of Antimanic Treatments: Meta-analysis of Randomized, Controlled Trials (2011) (233)
- Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. (2015) (233)
- Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. (2016) (221)
- Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. (2007) (218)
- Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. (2006) (217)
- Acamprosate for alcohol dependence? (2010) (214)
- Early-Onset Hypothesis of Antipsychotic Drug Action: A Hypothesis Tested, Confirmed and Extended (2005) (208)
- Olanzapine versus other atypical antipsychotics for schizophrenia. (2010) (204)
- Second‐generation antipsychotic effect on cognition in patients with schizophrenia—a meta‐analysis of randomized clinical trials (2015) (202)
- Valproate for schizophrenia. (2016) (191)
- Definitions of response and remission in schizophrenia: recommendations for their use and their presentation (2009) (190)
- Acamprosate for alcohol dependence. (2010) (177)
- Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method. (2015) (177)
- Detecting Neuroimaging Biomarkers for Schizophrenia: A Meta-Analysis of Multivariate Pattern Recognition Studies (2015) (174)
- Optimizing pharmacologic treatment of psychotic disorders (2003) (173)
- Shared decision making in psychiatry (2003) (173)
- Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. (2005) (171)
- Defining ‘Response’ in Antipsychotic Drug Trials: Recommendations for the Use of Scale-Derived Cutoffs (2007) (171)
- Shared decision making and long-term outcome in schizophrenia treatment. (2007) (167)
- Second-generation antipsychotics for major depressive disorder and dysthymia. (2010) (166)
- Dropout rates in randomised antipsychotic drug trials (2001) (159)
- Second-generation antipsychotics for schizophrenia: can we resolve the conflict? (2009) (158)
- Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. (2004) (156)
- Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. (2012) (156)
- Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later (2010) (156)
- Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. (2004) (155)
- Is the superior efficacy of new generation antipsychotics an artifact of LOCF? (2006) (155)
- Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. (2016) (152)
- Attitudes of psychiatrists toward antipsychotic depot medication. (2006) (150)
- Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis (2019) (146)
- What does the HAMD mean? (2013) (146)
- Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice (2009) (145)
- Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics (2011) (145)
- Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta‐analysis and meta‐regression analysis (2017) (142)
- Second-generation antipsychotics and constipation: A review of the literature (2011) (137)
- Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. (2016) (137)
- The Relative Sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in Antipsychotic Drug Trials (2006) (133)
- Personality disorders and violence (2008) (131)
- Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis (2016) (130)
- Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach. (2016) (129)
- Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. (2015) (129)
- Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence (2017) (127)
- Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis (2018) (127)
- Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies (2018) (126)
- Proton Magnetic Resonance Spectroscopy and Illness Stage in Schizophrenia—A Systematic Review and Meta-Analysis (2011) (125)
- Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. (2001) (124)
- Acamprosate supports abstinence, Naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes (2008) (123)
- Early prediction of antipsychotic nonresponse among patients with schizophrenia. (2007) (121)
- Aripiprazole versus other atypical antipsychotics for schizophrenia. (2014) (119)
- Evidence‐based guidelines for interpretation of the Panic Disorder Severity Scale (2009) (119)
- Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. (2018) (118)
- How to Obtain NNT from Cohen's d: Comparison of Two Methods (2011) (118)
- Network meta-analyses should be the highest level of evidence in treatment guidelines (2016) (116)
- Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. (2014) (113)
- Risperidone versus other atypical antipsychotics for schizophrenia. (2011) (110)
- Extrapolation between measures of symptom severity and change: An examination of the PANSS and CGI (2008) (107)
- Quetiapine versus other atypical antipsychotics for schizophrenia. (2010) (103)
- Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. (2019) (103)
- Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome (2010) (103)
- The Longitudinal Course of Schizophrenia Across the Lifespan: Clinical, Cognitive, and Neurobiological Aspects (2016) (101)
- Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective (2014) (100)
- The attitude of patients towards antipsychotic depot treatment (2007) (99)
- Equipercentile linking of the BPRS and the PANSS (2013) (99)
- Antidepressants for the negative symptoms of schizophrenia. (2006) (98)
- Combining randomized and non‐randomized evidence in network meta‐analysis (2017) (95)
- Tardive dyskinesia risk with first‐ and second‐generation antipsychotics in comparative randomized controlled trials: a meta‐analysis (2018) (95)
- Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. (2020) (94)
- Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study (2011) (91)
- Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. (2018) (91)
- Methodological issues in current antipsychotic drug trials. (2007) (90)
- Auditory hallucinations across the lifespan: a systematic review and meta-analysis (2017) (90)
- Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. (2001) (90)
- Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. (2017) (87)
- The concepts of remission and recovery in schizophrenia. (2006) (87)
- Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network meta‐analysis (2018) (87)
- Second-generation antipsychotics for obsessive compulsive disorder. (2010) (86)
- Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. (2015) (85)
- Ziprasidone versus other atypical antipsychotics for schizophrenia. (2009) (82)
- Second-generation antipsychotics for anxiety disorders. (2010) (82)
- How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis (2017) (82)
- Correlation between amygdala volume and age in bipolar disorder — A systematic review and meta-analysis of structural MRI studies (2010) (78)
- Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis (2017) (77)
- The clinical significance of cognition-focused interventions for cognitively impaired older adults: a systematic review of randomized controlled trials (2011) (77)
- Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: A systematic review of randomized trials (2005) (77)
- Benzodiazepines for schizophrenia. (2012) (73)
- How effective are common medications: a perspective based on meta-analyses of major drugs (2015) (72)
- Amitriptyline versus placebo for major depressive disorder. (2012) (69)
- Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs — An original patient data meta-analysis of the SPET and PET in vivo receptor imaging literature (2008) (69)
- Confirmation bias: why psychiatrists stick to wrong preliminary diagnoses (2011) (69)
- Specific Substantial Dysconnectivity in Schizophrenia: A Transdiagnostic Multimodal Meta-analysis of Resting-State Functional and Structural Magnetic Resonance Imaging Studies (2019) (68)
- Caregivers of patients with frontotemporal lobar degeneration: a review of burden, problems, needs, and interventions (2012) (68)
- Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. (2004) (67)
- The PANSS should be rescaled. (2010) (66)
- Medical decision making in antipsychotic drug choice for schizophrenia. (2004) (66)
- "How to speak to your psychiatrist": shared decision-making training for inpatients with schizophrenia. (2011) (66)
- Measurement-based psychiatry: definitions of response, remission, stability, and relapse in schizophrenia. (2006) (66)
- Evidence-based pharmacotherapy of schizophrenia. (2011) (65)
- Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials (2004) (64)
- Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. (2004) (63)
- Common pitfalls and mistakes in the set-up, analysis and interpretation of results in network meta-analysis: what clinicians should look for in a published article (2017) (62)
- Serotonin transporter polymorphisms and side effects in antidepressant therapy--a pilot study. (2006) (60)
- New generation antipsychotics for first episode schizophrenia. (2003) (60)
- Addressing missing outcome data in meta-analysis (2014) (60)
- Elaboration on the Early-Onset Hypothesis of Antipsychotic Drug Action: Treatment Response Trajectories (2010) (60)
- Carbamazepine for schizophrenia. (2014) (59)
- Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening? (2009) (58)
- How to read and understand and use systematic reviews and meta‐analyses (2009) (58)
- How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials (2018) (58)
- ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. (2006) (58)
- Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: A meta-analysis and cochrane review of randomized controlled trials (2013) (55)
- The Prevalence of Mental Illness in Homeless People in Germany. (2017) (55)
- Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis. (2020) (55)
- Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. (2015) (55)
- Psychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophrenia (2011) (54)
- Predicting antipsychotic drug response – Replication and extension to six weeks in an international olanzapine study (2008) (52)
- [Meta-analysis of effectiveness and tolerability of treatment of mild to moderate depression with St. John's Wort]. (2004) (52)
- On the concept of remission in schizophrenia (2007) (51)
- Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. (2021) (50)
- Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. (2018) (48)
- Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study (2019) (48)
- Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis (2019) (47)
- Carbamazepine augmentation for schizophrenia: how good is the evidence? (2002) (46)
- MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain? (2013) (46)
- Amisulpride is an “atypical” antipsychotic associated with low weight gain (2004) (46)
- Amisulpride versus other atypical antipsychotics for schizophrenia. (2010) (45)
- Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. (2014) (45)
- An approach for modelling multiple correlated outcomes in a network of interventions using odds ratios (2014) (45)
- Equipercentile linking of scales measuring functioning and symptoms: Examining the GAF, SOFAS, CGI-S, and PANSS (2014) (45)
- Evaluation of Differences in Individual Treatment Response in Schizophrenia Spectrum Disorders: A Meta-analysis. (2019) (45)
- Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia (2013) (45)
- Identifying a system of predominant negative symptoms: Network analysis of three randomized clinical trials (2016) (44)
- A systematic review of the clinical relevance of repetitive transcranial magnetic stimulation (2014) (43)
- Recent meta-analyses neglect previous systematic reviews and meta-analyses about the same topic: a systematic examination (2015) (43)
- Translating the HAM-D into the MADRS and vice versa with equipercentile linking. (2018) (43)
- Clozapine as a first‐ or second‐line treatment in schizophrenia: a systematic review and meta‐analysis (2018) (43)
- Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. (2011) (43)
- Haloperidol versus chlorpromazine for schizophrenia. (2008) (42)
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis (vol 382, pg 951, 2013) (2013) (41)
- Opioid antagonists for alcohol dependence. (2010) (41)
- Benzodiazepines for schizophrenia. (2007) (40)
- Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta‐analysis (2018) (39)
- Comparative remission rates of schizophrenic patients using various remission criteria (2008) (38)
- What does the MADRS mean? Equipercentile linking with the CGI using a company database of mirtazapine studies. (2017) (38)
- Polymorphisms in serotonergic pathways influence the outcome of antidepressant therapy in psychiatric inpatients. (2014) (37)
- Aripiprazole versus other atypical antipsychotics for schizophrenia. (2009) (37)
- Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms. (2019) (37)
- Effects of Short-Term Exercise Interventions on Behavioral and Psychological Symptoms in Patients with Dementia: A Systematic Review. (2016) (37)
- Evaluating the impact of imputations for missing participant outcome data in a network meta-analysis (2013) (37)
- Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: A systematic review, pairwise and network meta-analysis (2019) (36)
- Perphenazine for schizophrenia. (2005) (36)
- Translating the BDI and BDI-II into the HAMD and vice versa with equipercentile linking (2019) (36)
- Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms (2013) (36)
- Association of the Common MC4R rs17782313 Polymorphism With Antipsychotic-Related Weight Gain (2013) (36)
- Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis (2022) (35)
- The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. (2015) (34)
- Lithium for schizophrenia. (2015) (34)
- Biological v. psychosocial treatments: a myth about pharmacotherapy v. psychotherapy (2016) (34)
- Carbamazepine for schizophrenia and schizoaffective psychoses. (2002) (34)
- Physical Illness and Schizophrenia: A Review of the Evidence (2007) (33)
- Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention. (2015) (33)
- Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review (2021) (33)
- Defining therapeutic benefit for people with schizophrenia: Focus on negative symptoms (2015) (32)
- Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials (2011) (31)
- The Deceleration Capacity - a New Measure of Heart Rate Variability Evaluated in Patients With Schizophrenia and Antipsychotic Treatment (2013) (31)
- Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients (2000) (31)
- DRD4 48 bp VNTR but not 5-HT2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain (2009) (30)
- How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed? (2010) (30)
- Early improvement as a predictor of treatment response and remission in patients with schizophrenia: A pooled, post-hoc analysis from the asenapine development program (2014) (30)
- Antipsychotic drugs for elderly patients with schizophrenia: A systematic review and meta-analysis (2018) (30)
- Unanswered questions in schizophrenia clinical trials. (2007) (30)
- CYP1A2*1D and *1F Polymorphisms Have a Significant Impact on Olanzapine Serum Concentrations (2015) (29)
- Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends (2022) (29)
- Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method (2017) (29)
- Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis (2020) (27)
- Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis (2018) (27)
- Lithium for schizophrenia. (2007) (27)
- Chlorpromazine versus every other antipsychotic for schizophrenia: A systematic review and meta-analysis challenging the dogma of equal efficacy of antipsychotic drugs (2014) (27)
- Psychiatric treatment guidelines: doctors’ non‐compliance or insufficient evidence? (2007) (26)
- Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. (2014) (25)
- Doxepin Plasma Concentrations: Is There Really a Therapeutic Range? (2001) (25)
- Equipercentile linking of the Brief Psychiatric Rating Scale and the Clinical Global Impression Scale in a catchment area (2012) (24)
- Publication bias and small-study effects magnified effectiveness of antipsychotics but their relative ranking remained invariant. (2016) (24)
- Comparative efficacy and acceptability of antidepressants, psychological interventions, and their combination for depressive disorder in children and adolescents: protocol for a network meta-analysis (2017) (24)
- Psychometric analysis in support of shortening the Scale for the Assessment of Negative Symptoms (2013) (23)
- Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia. (2014) (23)
- Early symptom response to antipsychotic medication as a marker of subsequent symptom change: An eighteen-month follow-up study of recent episode schizophrenia (2012) (23)
- The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching Antipsychotics. (2016) (23)
- Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia (2019) (22)
- 60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Meta-regression of predictors of placebo response (2018) (22)
- How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single-group meta-analysis (2020) (22)
- Psychiatric Disorder (2020) (22)
- Is placebo response in antidepressant trials rising or not? A reanalysis of datasets to conclude this long-lasting controversy (2018) (22)
- Do antipsychotic drugs lose their efficacy for relapse prevention over time? (2017) (22)
- Carbamazepine for schizophrenia. (2007) (22)
- Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia: A Meta-analysis. (2021) (21)
- Pharmacotherapy in the treatment of patients with borderline personality disorder: results of a survey among psychiatrists in private practices (2014) (21)
- Antidepressants might work for people with major depression: where do we go from here? (2018) (21)
- Sertindole versus other atypical antipsychotics for schizophrenia. (2009) (21)
- Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis. (2019) (20)
- European psychiatric treatment guidelines: is the glass half full or half empty? (2005) (20)
- Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: Analysis of amisulpride vs placebo in three clinical trials (2014) (20)
- Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning (2020) (20)
- How do psychiatrists choose among different antipsychotics? (2005) (20)
- A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders (2021) (20)
- Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials (2022) (19)
- Family interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. (2022) (19)
- Using the contribution matrix to evaluate complex study limitations in a network meta-analysis: a case study of bipolar maintenance pharmacotherapy review (2016) (19)
- Efficacy, acceptability, and tolerability of all available treatments for insomnia in the elderly: a systematic review and network meta‐analysis (2020) (19)
- Long-acting injection antipsychotic medications in the management of schizophrenia (2015) (19)
- Improvement of the physical health of people with mental illness. (2006) (18)
- Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems. (2003) (18)
- Perazine for schizophrenia. (2006) (18)
- Physicians' and patients' involvement in relapse prevention with antipsychotics in schizophrenia. (2005) (18)
- Imputation of response rates from means and standard deviations in schizophrenia (2013) (18)
- Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies. (2017) (18)
- Response rates in patients with schizophrenia and positive symptoms receiving cognitive behavioural therapy: a systematic review and single-group meta-analysis (2018) (18)
- Schizophrenia, primary negative symptoms, and soft outcomes in psychiatry (2017) (18)
- Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial (2020) (18)
- Pharmacological Treatment of Schizophrenia (2013) (17)
- A living meta-ecological study of the consequences of the COVID-19 pandemic on mental health (2021) (17)
- Zotepine versus other atypical antipsychotics for schizophrenia. (2010) (17)
- Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis (2022) (16)
- Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis. (2020) (16)
- Psychiatric decision making in the adoption of a new antipsychotic in Germany. (2006) (16)
- Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis (2019) (16)
- [Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview]. (2008) (16)
- Attaining and sustaining remission of predominant negative symptoms (2013) (16)
- Psychiatrists' decision making between branded and generic drugs (2013) (16)
- Increasing placebo response in antipsychotic drug trials: let's stop the vicious circle. (2013) (15)
- [Psychiatric patients and relatives instruct German police officers - an anti-stigma project of "BASTA - the alliance for mentally ill people"]. (2007) (14)
- Maintenance treatment with antipsychotic drugs for schizophrenia. (2020) (14)
- Do antipsychotics lead to cognitive impairment in dementia? A meta-analysis of randomised placebo-controlled trials (2017) (14)
- Increasing antipsychotic dose for non response in schizophrenia. (2015) (14)
- Psychological interventions for positive symptoms in schizophrenia: protocol for a network meta-analysis of randomised controlled trials (2018) (13)
- No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: systematic review (2019) (13)
- Aberrant striatal dopamine links topographically with cortico-thalamic dysconnectivity in schizophrenia. (2020) (13)
- Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial (2020) (13)
- The controversy about cognitive behavioural therapy for schizophrenia (2019) (13)
- Substance dependence. (1998) (13)
- Results of treatment of schizophrenia: is the glass half full or half empty? (1999) (13)
- Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes. (2015) (13)
- Are Randomized Controlled Trials on Pharmacotherapy and Psychotherapy for Positive Symptoms of Schizophrenia Comparable? A Systematic Review of Patient and Study Characteristics. (2019) (12)
- Are all antipsychotic drugs the same? (2011) (12)
- Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia (2015) (12)
- Linking the Mini-Mental State Examination, the Alzheimer’s Disease Assessment Scale–Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil (2020) (12)
- The Impact of the COVID-19 Pandemic and Associated Control Measures on the Mental Health of the General Population (2022) (12)
- Should We Treat Depression with drugs or psychological interventions? A Reply to Ioannidis (2011) (12)
- Language bias in neuroscience—is the Tower of Babel located in Germany? (2004) (12)
- Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study (2021) (11)
- Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. (2014) (11)
- Physical Illness and Schizophrenia: Method (2007) (11)
- The impact of trial characteristics on premature discontinuation of antipsychotics in schizophrenia (2013) (11)
- Haloperidol versus chlorpromazine for treatment of schizophrenia. (2008) (10)
- Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala: lack of association with weight gain in psychiatric inpatients treated with olanzapine or clozapine. (2012) (10)
- Associations between individual antipsychotics and the risk of arrests and convictions of violent and other crime: a nationwide within-individual study of 74 925 persons (2021) (10)
- Is there compelling evidence that schizophrenia long‐term treatment guidelines should be changed? (2018) (10)
- Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia (2021) (10)
- Quetiapine versus other atypical antipsychotics for schizophrenia (Review) (2010) (10)
- Sleeplessness (1885) (10)
- Commentary on strategies for switching antipsychotics (2008) (10)
- Eleven‐year clinical outcome of schizophrenia in Bali (2006) (10)
- Delayed- and early-onset hypotheses of antipsychotic drug action in the negative symptoms of schizophrenia (2012) (10)
- Perphenazine for schizophrenia. (2015) (10)
- Enthusiasm and Skepticism About Using National Registers to Analyze Psychotropic Drug Outcomes. (2018) (9)
- Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art (2022) (9)
- Comparative Efficacy and Tolerability of 32 Oral Antipsychotics for the Acute Treatment of Adults With Multi-Episode Schizophrenia: A Systematic Review and Network Meta-Analysis. (2020) (9)
- Benperidol for schizophrenia. (2005) (9)
- Prolactin levels influenced by antipsychotic drugs in schizophrenia: A systematic review and network meta-analysis (2021) (9)
- Do patients with paranoid and disorganized schizophrenia respond differently to antipsychotic drugs? (2014) (9)
- Fat Mass and Obesity-Related Gene Variants rs9939609 and rs7185735 are Associated with Second-Generation Antipsychotic-Induced Weight Gain (2018) (8)
- Patients' acceptance of the deltoid application of risperidone long-acting injection (2012) (8)
- Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia (2007) (8)
- ANTIPSYCHOTIC COMBINATIONS VERSUS MONOTHERAPY IN SCHIZOPHRENIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (2008) (8)
- Are patients with schizophrenia under-treated with second-generation antipsychotics? A pilot study of the prescription practices of German psychiatrists. (2003) (8)
- Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. (2015) (8)
- The SWITCH study: rationale and design of the trial (2016) (7)
- Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Pro12Ala (2012) (7)
- Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients (2021) (7)
- Zotepine versus other atypical antipsychotics for schizophrenia. (2010) (7)
- Optimizing pharmacologic treatment of psychotic disorders. Commentary (2003) (7)
- Haloperidol versus first generation antipsychotics for schizophrenia (2012) (7)
- Relationship between costs and symptoms in schizophrenia patients treated with antipsychotic medication: a review. (2004) (7)
- Rasch analysis of the PANSS negative subscale and exploration of negative symptom trajectories in first-episode schizophrenia – data from the OPTiMiSE trial (2020) (7)
- CATIE findings revisited. (2009) (7)
- Prevalence , impact of medications and disparities in health care WPA EDUCATIONAL MODULE (2011) (7)
- Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis. (2022) (7)
- Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. (2014) (7)
- Call for a European Guidelines Institute (2006) (7)
- medication into perspective: review of meta-analyses Putting the efficacy of psychiatric and general medicine (2012) (6)
- Antipsychotic drugs v. barbiturates or benzodiazepines used as active placebos for schizophrenia: a systematic review and meta-analysis (2019) (6)
- Multifactorial barriers in the implementation of schizophrenia and psychosocial therapies guidelines: A quantitative study across different professions (2021) (6)
- Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders (2022) (6)
- Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia (2022) (6)
- Impact of non-uniform attenuation correction in a dynamic [18F]-FDOPA brain PET/MRI study (2019) (6)
- Efficient two-step multivariate random effects meta-analysis of individual participant data for longitudinal clinical trials using mixed effects models (2019) (6)
- Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study. (2020) (6)
- Hostility and aggressive behaviour in first episode psychosis: Results from the OPTiMiSE trial (2020) (6)
- Iconography : Psychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophrenia (2011) (5)
- Optimal Dose of Selective Serotonin Reuptake Inhibitors, Venlafaxine, and Mirtazapine in Major Depression: A Systematic Review and Dose-Response Meta-Analysis. (2020) (5)
- A novel approach to measuring response and remission in schizophrenia in clinical trials (2017) (5)
- Antipsychotic drugs for prevention of relapse (2012) (5)
- Lithium for schizophrenia (Review) (2009) (5)
- Quetiapine versus other atypical antipsychotics for schizophrenia. (2013) (5)
- Variability of cerebral blood fow deficits in99mTc-HMPAO SPECT in patients with Alzheimer's disease (2005) (5)
- An efficient way to assess the effect of COVID-19 on mental health in the general population (2021) (5)
- Has Research Informed Us on the Practical Drug Treatment of Schizophrenia? (2007) (5)
- A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design (2019) (5)
- Clozapine in treatment-resistant schizophrenia (2017) (5)
- Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials. (2022) (5)
- Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis (2021) (4)
- Possibly no baseline severity effect for antidepressants versus placebo but for antipsychotics. Why? (2018) (4)
- Medical decision making in the mental health field. (2005) (4)
- Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials (2016) (4)
- Evaluating pimavanserin as a treatment for psychiatric disorders: A pharmacological property in search of an indication (2021) (4)
- What is the "best intro"-explanatory versus pragmatic antipsychotic drug trials. (2020) (4)
- Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder (2021) (4)
- Vitruvian plot: a visualisation tool for multiple outcomes in network meta-analysis (2022) (4)
- Critical trial-related criteria in acute schizophrenia studies (2012) (4)
- Efficacy of antipsychotic drugs for schizophrenia – Authors' reply (2013) (4)
- Linking the Clinical Dementia Rating Scale-Sum of Boxes, the Clinician's Interview-Based Impression Plus Caregiver Input, and the Clinical Global Impression Scale: Evidence based on Individual Participant Data from Five Randomized Clinical Trials of Donepezil. (2021) (4)
- Lithium for schizophrenia. (2003) (4)
- Treatment Goals for Patients with Schizophrenia — A Narrative Review of Physician and Patient Perspectives (2020) (4)
- Accounting for uncertainty due to ‘last observation carried forward’ outcome imputation in a meta‐analysis model (2015) (4)
- Proton Magnetic Resonance Spectroscopy and Illness Stage in Schizophrenia—A Systematic Review and (2011) (4)
- Second-generation antipsychotics and quality of life in schizophrenia. (2016) (3)
- Valproate for schizophrenia. (2008) (3)
- Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. (2022) (3)
- Comparative effi cacy and tolerability of antidepressants for major depressive disorder in children and adolescents : a network meta-analysis (2016) (3)
- Are new drugs for schizophrenia better than old ones? – Authors' reply (2009) (3)
- Metabolic Adverse Effects Associated with Antipsychotic Medications (2011) (3)
- EARLY PREDICTION OF ANTIPSYCHOTIC NON-RESPONSE USING RECEIVER-OPERATOR CURVES AND SENSITIVITY-SPECIFICITYANALYSES (2008) (3)
- Should ‘typical’, first-generation antipsychotics no longer be generally used in the treatment of schizophrenia? (2021) (3)
- Correction: Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study (2019) (3)
- Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia. (2022) (3)
- Meta-analysis of amisulpride — A selective dopamine receptor antagonist with an “atypical” profile (2000) (3)
- Translating research into clinical practice: critical interpretation of clinical trials in schizophrenia (2006) (3)
- Antipsychotic drugs: from ‘major tranquilizers’ to Neuroscience-based-Nomenclature (2020) (3)
- Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST). (2023) (3)
- Antipsychotic dose reduction compared to dose continuation for people with schizophrenia (2021) (3)
- Examining Side Effect Variability of Antipsychotic Treatment in Schizophrenia Spectrum Disorders: A Meta-analysis of Variance. (2021) (3)
- Benperidol for schizophrenia. (2005) (3)
- Personality: Neurobehavioural Foundation and Pharmacological Protocols (2014) (3)
- Perazine for schizophrenia (Review) (2014) (3)
- Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: protocol for a systematic review and network meta-analysis of randomized controlled trials (2021) (3)
- Psychosocial treatments for relapse prevention in schizophrenia: study protocol for a systematic review and network meta-analysis of randomised evidence (2020) (3)
- Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs (2022) (3)
- The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis. (2022) (3)
- The role of depression in the prediction of a “late” remission in first-episode psychosis: An analysis of the OPTiMiSE study (2021) (3)
- Clozapine, Long-Acting Injectables (and Polypharmacy?) Superior in U.S. and International Registries. (2021) (2)
- How Efficacious Are Antipsychotic Drugs for Schizophrenia? An Interpretation Based on 13 Effect Size Indices. (2021) (2)
- New generation versus conventional antipsychotics (2003) (2)
- About the issue of including or excluding studies from China in systematic reviews (2022) (2)
- 31.3 CLINICAL UTILITY OF MRI SCANNING IN FIRST EPISODE PSYCHOSIS (2018) (2)
- PHARMACOGENETICS: GENOTYPING OF CYTOCHROMES P450 2D6 AND 2C19 IN PSYCHIATRIC PATIENTS TREATED WITH TRICYCLIC ANTIDEPRESSANTS (TCA) OR NEUROLEPTICS. (1999) (2)
- Pretrial medication bias in randomized antipsychotic drug trials. (2007) (2)
- Language Bias in Neuroscience – Is the Tower of Babel located in Germany? (2004) (2)
- Second‐generation antipsychotic drugs for major depressive disorder (2009) (2)
- [Considerations about the efficacy of psychopharmacological drugs]. (2011) (2)
- Pharmacological approaches to treatment (2020) (2)
- Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia (2022) (2)
- Second-generation antipsychotic drugs for obsessive compulsive disorder (2009) (2)
- Valproate for schizophrenia. (2016) (2)
- Physical Illness and Schizophrenia: Results (2007) (2)
- Lithium for schizophrenia: A systematic review and meta-analysis (2000) (2)
- P.2.047 Shared decision making on antipsychotic drug choice for inpatients with schizophrenia (2004) (2)
- PREVALENCE AND SEVERITY OF ANTIPSYCHOTIC RELATED CONSTIPATION (2010) (2)
- Issues in psychopharmacology. (2007) (2)
- [Therapeutic decisions based on meta analyses]. (2008) (2)
- Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis (2018) (2)
- Amygdala volume for bipolar affective disorder - a meta-analysis (2007) (2)
- Valproate for schizophrenia (Review) (2010) (2)
- Baseline levels of C-reactive protein and proinflammatory cytokines are not associated with early response to amisulpride in patients with First Episode Psychosis: the OPTiMiSE cohort study (2021) (2)
- Clozapine versus olanzapine for people with schizophrenia (2018) (2)
- Clozapine versus risperidone for people with schizophrenia (2018) (2)
- Preface: Treatment optimization in schizophrenia through active patient management – proceedings from two European consensus meetings (2009) (2)
- Effects of psychological treatments on functioning in people with Schizophrenia: a systematic review and meta-analysis of randomized controlled trials. (2022) (2)
- How should patient decision aids for schizophrenia treatment be designed? - A scoping review (2023) (2)
- 14:00 MULTIPLE-TREATMENTS META-ANALYSIS ON THE EFFICACY, ACCEPTABILITY AND TOLERABILITY OF 15 ANTIPSYCHOTICS DRUGS IN SCHIZOPHRENIA (2012) (2)
- Different antipsychotics produce similar, small improvements in psychosocial functioning at one year in people with schizophrenia (2007) (2)
- Drowning in Numbers–what Psychiatrists Mean when Talking to Patients about Probabilities of Risks and Benefits of Medication (2010) (2)
- New insight into the CATIE study by constrained confidence partitioning. An innovative technique towards personalized antipsychotic drug therapy in schizophrenia treatment (2021) (1)
- Rapid Detection Of The Intermediate Metabolizer Associated CYP2D6 Polymorphisms *9 And *17 With Real Time PCR: 124 (2005) (1)
- Antipsychotic Medications: Enhancing Use to Improve Outcomes. (2021) (1)
- Review: new generation antipsychotics do not induce fewer extrapyramidal side effects than low potency antipsychotics (2003) (1)
- Often claimed, rarely tested: differences in individual drug response (2018) (1)
- Physical Illness & Schizophrenia - A Review of the Evidence (2007) (1)
- How long do psychiatrists wait for response before they switch to another antipsychotic? (2007) (1)
- Perazine for schizophrenia. (2014) (1)
- Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysis (2022) (1)
- An update of meta-analyses on second-generation antipsychotic drugs for schizophrenia (2009) (1)
- Optimal dosing of antidepressant drugs - Authors' reply. (2019) (1)
- Comparative efficacy and acceptability of antidepressants , psychological interventions , and their combination for depressive disorder in children and adolescents (2017) (1)
- DOXEPIN SERUM CONCENTRATIONS: IS THERE REALLY A THERAPEUTIC RANGE? (1999) (1)
- P.3.030 Cochrane meta-analysis: antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms (2005) (1)
- Metabolic side effects in persons with schizophrenia during mid‐ to long‐term treatment with antipsychotics: a network meta‐analysis of randomized controlled trials (2023) (1)
- Measuring Outcomes in Schizophrenia and Examining Their Clinical Application (2014) (1)
- C.13.03 Translating the evidence on the clinical benefits of antipsychotics for routine practice (2012) (1)
- From conventional to living guidelines - faster updates for better informed guidance? A scoping review. (2022) (1)
- S.05.01 Understanding individual variability in response: a review of the evidence (2009) (1)
- Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorder (2021) (1)
- Essential Evidence-Based Psychopharmacology: Evidence-based pharmacotherapy of schizophrenia (2012) (1)
- Dr. Correll and Colleagues Reply (2005) (1)
- P.3.d.021 Early improvement as a predictor of treatment response and remission in patients with acute schizophrenia: effects of asenapine (2013) (1)
- Predicting psychotic relapse following randomised discontinuation of paliperidone in individuals with schizophrenia or schizoaffective disorder: an individual participant data analysis. (2023) (1)
- Scalability of the Positive and Negative Syndrome Scale in first‐episode schizophrenia assessed by Rasch models (2022) (1)
- Poster #216 IS HALOPERIDOL MORE EFFECTIVE THAN OTHER FIRST-GENERATION ANTIPSYCHOTICS IN SCHIZOPHRENIA? A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (2012) (1)
- State of the art reporting of network meta-analyses (2014) (1)
- O7.4. SYSTEMATIC REVIEW, META-ANALYSIS AND META-REGRESSION OF PREDICTORS OF PLACEBO RESPONSE IN ACUTE SCHIZOPHRENIA (2018) (1)
- Defining response, remission and recovery in schizophrenia (2007) (1)
- Examining side effect variation in antipsychotic treatment and schizophrenia spectrum disorders (2020) (1)
- Α Markov model for longitudinal studies with incomplete dichotomous outcomes (2016) (1)
- META-ANALYSES ON DOUBLE-BLIND RCTS ADDING DRUGS WITH ANTI-INFLAMMATORY PROPERTIES TO ANTIPSYCHOTIC MEDICATION (2014) (1)
- Quantifying the heterogeneity of cognitive functioning in Alzheimer’s disease to extend the placebo-treatment dichotomy: Latent class analysis of individual-participant data from five pivotal randomized clinical trials of donepezil (2021) (1)
- P.3.d.069 How many patients with schizophrenia do not respond to antipsychotic drugs? (2015) (1)
- Maintenance antipsychotic trials and the effect of withdrawal – Authors' reply (2022) (1)
- A tool to assess risk of bias in studies estimating the prevalence of mental health disorders (RoB-PrevMH) (2023) (1)
- The Dopamine D4 Receptor 48 Base Pair Repeat Polymorphism Influences Antipsychotic Induced Body Weight Gain. A Preliminary Report: 123 (2005) (1)
- Selective dopamine receptor antagonists with an ‘atypical’ profile? (2000) (1)
- Early- and subsequent- response of cognitive functioning in Alzheimer's disease: Individual-participant data from five pivotal randomized clinical trials of donepezil. (2022) (1)
- Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia (2021) (1)
- Mersey Care NHS Trust, Liverpool UK (2018) (1)
- Early prediction of non-response - when should antipsychotic drugs be switched? (2007) (1)
- Second‐generation antipsychotic drugs for anxiety disorders (2009) (1)
- What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial (2022) (1)
- DSM-III-R change in definition might have affected placebo response to antidepressants - Authors' reply. (2017) (1)
- SERUM LEVELS AND SIDE-EFFECTS OF TRICYCLIC ANTIDEPRESSANTS WITH ADJUNCTIVE PAROXETINE. A PROSPECTIVE STUDY. (1999) (1)
- Cognitive impairment networks in Alzheimer's disease: Analysis of three double-blind randomized, placebo-controlled, clinical trials of donepezil (2022) (1)
- Clinical implications of Brief Psychiatric Rating Clinical implications of Brief Psychiatric Rating (2005) (1)
- Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe (2022) (1)
- Erratum: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis (The Lancet (2013) 382 (951-962)) (2013) (1)
- Stratification and prediction of remission in first-episode psychosis patients OPTIMISE (2019) (0)
- S146. ASSOCIATION OF IMPAIRED MODEL-FREE DECISION-MAKING WITH ABERRANT STRIATAL DOPAMINE, BRAIN ACTIVATION, AND COGNITIVE DIFFICULTIES IN PATIENTS WITH SCHIZOPHRENIA DURING PSYCHOTIC REMISSION (2020) (0)
- T216. VARIATION IN SIDE EFFECTS TO ANTIPSYCHOTIC TREATMENT ACROSS SCHIZOPHRENIA SPECTRUM DISORDERS (2020) (0)
- Schizophrenia and physical diseases: review (2008) (0)
- HTR1A and serotonin transporter gene polymorphisms influence therapeutic response (2007) (0)
- Prediction of drop-out and functional impairment in recent-onset schizophrenia spectrum disorders (2021) (0)
- Validation of the Glasgow Antipsychotic Side-Effect Scale (GASS) in an Italian Sample of Patients with Stable Schizophrenia and Bipolar Spectrum Disorders (2022) (0)
- Author response for "Efficacy, acceptability and tolerability of all available treatments for insomnia in the elderly: a systematic review and network meta‐analysis" (2020) (0)
- The implications of relapses on the evolution of schizophrenia. How to prevent them? (2006) (0)
- Switching antipsychotic for non response in schizophrenia (2015) (0)
- S.05.03 Atypical antipsychotics in bipolar disorder and schizophrenia: similarities and discrepancies (2013) (0)
- Personalized Prediction of Alzheimer's Disease and Its Treatment Effects by Donepezil: An Individual Participant Data Meta-Analysis of Eight Randomized Controlled Trials. (2022) (0)
- Often claimed, rarely tested: individual drug response in antipsychotic drug trials (2018) (0)
- Authors' reply. (2016) (0)
- SARS genome patent : to manage and to share (2005) (0)
- P.2.e.003 Second generation antipsychotics versus haloperidol in the treatment of acute mania: a meta-analysis (2006) (0)
- Update Depotantipsychotika (2023) (0)
- Dr. Hamann and Colleagues Reply (2006) (0)
- A Meta-analysis of studies with the atypical antipsychotic amisulpride (2003) (0)
- What can we learn from the recent network meta-analyses of antipsychotic drugs? (2019) (0)
- In Reply. (2018) (0)
- Authors' reply (New generation versus conventional antipsychotics) (2003) (0)
- Prospective CYP2D6 genotyping in psychiatric inpatients. A preliminary report. (2003) (0)
- P.3.d.056 Treatment strategies in case of non-response in schizophrenia: increasing the antipsychotic dose or switching the antipsychotic drug versus continuation of the same antipsychotic dose or drug (2016) (0)
- The placebo effect in psychosis: why it matters and how to measure it (2023) (0)
- Linkage of Young Mania Rating Scale to Clinical Global Impression Scale to Enhance Utility in Clinical Practice and Research Trials (2022) (0)
- Confidence of evidence should be considered in ranking of treatments in the network meta-analysis - Authors' reply. (2022) (0)
- Antipsychotic-induced akathisia in adults with acute schizophrenia: A systematic review and dose-response meta-analysis (2023) (0)
- Challenges and options in the treatment of schizophrenia (2007) (0)
- EPA-1057 – Is There A Comparable Efficacy Between Haloperidol and the Other First-Generation Antipsychotics in Schizophrenia? A Cochrane Review of Randomized Controlled Trials (2014) (0)
- Benperidol for schizophrenia (Review) (2010) (0)
- New generation versus conventional antipsychotics. Authors' reply (2003) (0)
- Lithium for schizophrenia (Withdrawn Paper. 2007, art. no. CD003834) (2007) (0)
- T6. SECOND GENERATION ANTIPSYCHOTIC DRUGS AND MORTALITY: A META-ANALYSIS OF PLACEBO-CONTROLLED RANDOMISED CONTROLLED TRIALS (2018) (0)
- [Are negative cognitions symptoms of depression or also an expression of personality traits?]. (1997) (0)
- P.3.d.067 Long-acting injectable vs oral antipsychotics for hospitalisation prevention in schizophrenia: a systematic review/meta-analysis of cohort studies (2015) (0)
- Using the contribution matrix to evaluate complex study limitations in a network meta-analysis: a case study of bipolar maintenance pharmacotherapy review (2016) (0)
- Clozapine versus quetiapine for people with schizophrenia (2018) (0)
- EPA-1671 – Diagnosing Schizophrenia Using Neuroimaging: A Meta-analysis of Multivariate Pattern Recognition Studies (2014) (0)
- Title Optimal dose of selective serotonin reuptake inhibitors , venlafaxine , and mirtazapine in major depression : a systematic review and dose-response meta-analysis (2019) (0)
- Sharing information across patient subgroups to draw conclusions from sparse treatment networks (2023) (0)
- Short-Lived Delirium Caused by Single-Shot Corticosteroids (2014) (0)
- Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis. (2021) (0)
- P03-376 - The Relevance of Doses for Comparing Haloperidol, Risperidone and Olanzapine (2010) (0)
- Reply to The Importance of Negative Comorbidity (2009) (0)
- Aripiprazole versus other atypical antipsychotics for schizophrenia. (2013) (0)
- Evidence-based Psychiatric Care: the Whys (2015) (0)
- Academic Highlights: New Developments in the Treatment of Schizophrenia. [CME] (2007) (0)
- The Influence of Therapeutic Drug Monitoring (TDM) and Objective Symptom Rating for Prediction of Antipsychotic Response to Second-Generation Antipsychotic Drugs (2008) (0)
- Intermediate Metabolizers And Increased Risk Of Adverse Events in Psychiatric In-patients. an Update Including All Relevant Alleles With Reduced Function and Applying Gene-dose for Analysis: 170 (2005) (0)
- Can we inflate effect size and thus increase chances of producing “positive” results if we raise the baseline threshold in schizophrenia trials? (2013) (0)
- Optimizing subjective wellbeing with amisulpride in first episode schizophrenia or related disorders. (2022) (0)
- Shared Decision Making in Schizophrenia Treatment. Authors' reply (2008) (0)
- T200. METABOLIC SIDE EFFECTS OF ANTIPSYCHOTIC DRUGS – PROTOCOL OF A SYSTEMATIC REVIEW AND NETWORK- METAANALYSIS (2020) (0)
- Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia (2022) (0)
- Blinding successfulness in antipsychotic trials of acute treatment for schizophrenia: a systematic review (2023) (0)
- Systematic Review Or Meta-Analysis Efficacy, acceptability, and tolerability of all available treatments for insomnia in the elderly: a systematic review and network meta-analysis (2020) (0)
- Physical Illness and Schizophrenia: References (2007) (0)
- Placebo versus no treatment for people with schizophrenia (2023) (0)
- Gauging the Scope for Precision Medicine: Evaluating Individual Differences in Side Effects to Antipsychotic Treatment (2020) (0)
- COMAD : COmprehensive Meta-Analysis for Depression [ PROTOCOL ] (2012) (0)
- Physical Illness and Schizophrenia: Introduction (2007) (0)
- Efficacy and acceptability of pharmacological interventions for the treatment of antipsychotic-related weight gain and metabolic abnormalities : a systematic review and network meta-analysis (2018) (0)
- INITIAL SEVERITY AND EFFICACY OF ANTIPSYCHOTICS FOR SCHIZOPHRENIA: INDIVIDUAL LEVEL ANALYSES OF SIX PLACEBO-CONTROLLED STUDIES (2015) (0)
- P.3.d.031 Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis (2017) (0)
- Cognitive behavioural therapy plus standard care for first episode psychosis (2022) (0)
- Cortico-thalamic dysconnectivity links with aberrant striatal dopamine in schizophrenia A simultaneous 18F-DOPA-PET/resting-state fMRI study (2019) (0)
- DB01-02 - Polypharmacy Should be Avoided (2012) (0)
- Maintenance Treatment With Antipsychotic Drugs in Schizophrenia: A Cochrane Systematic Review and Meta-analysis. (2022) (0)
- Application of research evidence in clinical practice (2020) (0)
- Antipsychotic drugs for relapse prevention in schizophrenia – Authors' reply (2012) (0)
- PHARMACOLOGICAL AUGMENTATION STRATEGIES FOR SCHIZOPHRENIA PATIENTSWITH INSUFFICIENT RESPONSE TO CLOZAPINE (2012) (0)
- Muscarinic Cholinergic Receptor Agonists and Antagonists (2015) (0)
- Bipolar treatment efficacy - Authors' reply. (2014) (0)
- Clozapine resistance—Augmentation strategies (2013) (0)
- Drs Leucht and Fleischhacker Reply (2009) (0)
- Cochrane reviews: their importance for psychiatry (2006) (0)
- Use of Clozapine in Schizophrenia-Reply. (2016) (0)
- Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic and network meta-analysis. (2018) (0)
- Poster #208 NEW RESULTS ALTER BALANCE OF EVIDENCE IN META-ANALYSIS OF LONG-ACTING INJECTABLE VS. ORAL ANTIPSYCHOTICS IN SCHIZOPHRENIA (2012) (0)
- Concept of the Munich/Augsburg Consortium Precision in Mental Health for the German Center of Mental Health (2022) (0)
- O7.3. DOSE-RESPONSE META-ANALYSIS TO IDENTIFY THE OPTIMUM AND EQUIVALENT DOSES OF ANTIPSYCHOTIC DRUGS FOR SCHIZOPHRENIA (2018) (0)
- Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials (2023) (0)
- Antipsychotics for schizophrenia and substance misuse – Authors' reply (2020) (0)
- Guideline for schizophrenia: implementation status and attitude toward an upcoming living guideline. (2023) (0)
- P.3.031 Is there enough evidence for add-on treatment with benzodiazepines in schizophrenia? A meta-analysis of randomised controlled trials (2012) (0)
- Predictive Validity (2022) (0)
- S230. Convergence of Specifically Altered Intrinsic Brain Connectivity and Aberrant Brain Volume in Schizophrenia Transdiagnostic Multimodal Meta-Analysis of Resting-State Functional and Structural MRI (2018) (0)
- Title Dose equivalents of antidepressants : Evidence-based recommendations from randomized controlled trials (2018) (0)
- Review: little evidence to support dose escalation of selective serotonin reuptake inhibitors in non-responders (2007) (0)
- A meta-analysis comparing “atypical” antipsychotis with low-potency conventional antipsychotics. Is less more? (2003) (0)
- Impact of medical comorbidities on patients with severe mental illness (2007) (0)
- Genetic association of the rs17782313 polymorphism with antipsychotic-induced weight gain (2023) (0)
- How Reliable Are Critical Error Calculations ? (2006) (0)
- S.2.05 Psychoeducation and shared decision making as a way to reduce non-compliance in mental disorders (2011) (0)
- Generalizability of the Results of Efficacy Trials in First-Episode Schizophrenia: Comparing Outcome and Study Discontinuation of Groups of Participants in the Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial. (2023) (0)
- Second-generation-antipsychotic drugs and short-term-mortality: A meta-analysis of placebo-controlled randomized controlled trials (0)
- Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia-Reply. (2021) (0)
- What can we learn from recent cohort, national databases and meta-analytic studies for the clinical care of schizophrenia? (2019) (0)
- Antipsychotic drugs and their effects on cognitive function: protocol for a systematic review, pairwise, and network meta-analysis (2023) (0)
- Sesgo lingüístico en neurociencia: ¿está situada la Torre de Babel en Alemania? (2004) (0)
- Do schizophrenia patients want to be involved in their treatment? - Reply (2006) (0)
- 1 Proton Magnetic Resonance Spectroscopy and Illness Stage in Schizophrenia – A Systematic Review and Meta-Analysis (2015) (0)
- Clinician- versus caregiver-rated scales as outcome measures of repetitive-restricted behaviors in clinical trials of autism: A systematic review and meta-analysis (2023) (0)
- Cognitive behavioural therapy without medication for schizophrenia (2022) (0)
- CURRENT STATUS IN THE TIME COURSE OF ANTIPSYCHOTIC DRUG EFFECT, EARLY RESPONSE PREDICTION, EARLY SWITCH STUDIES AND RESEARCH ON TRAJECTORIES OF RESPONSE TO ANTIPSYCHOTICS (2010) (0)
- M201. MODERATORS OF WEIGHT GAIN IN RANDOMIZED CONTROLLED TRIALS OF SCHIZOPHRENIA – A META-REGRESSION ANALYSIS (2020) (0)
- Overstatement in article (2015) (0)
- 17.1 PREDICTORS OF RELAPSE IN FIRST EPISODE PSYCHOSIS PATIENTS IN REMISSION (2019) (0)
- C.03.02 Early predictors–areviewofcurrent knowledge (2008) (0)
- S204. REDUCTION OF ANTIPSYCHOTIC DOSES AND POLYPHARMACY: TWO COCHRANE REVIEWS (2020) (0)
- S235. MAINTENANCE TREATMENT WITH ANTIPSYCHOTIC DRUGS IN SCHIZOPHRENIA – SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS (2018) (0)
- Mega-review of meta-analyses investigating the short-term efficacy of pharmacologic augmentation strategies of antipsychotics in patients with schizophrenia (2016) (0)
- Review: Antipsychotic drugs improve symptoms, with different levels of side effects, in schizophrenia (2013) (0)
- [Fugue and suicide]. (2003) (0)
- P.3.d.029 Analyzing the efficacy of second-generation antipsychotic drugs in treatment-resistant schizophrenia: a meta-analysis (2014) (0)
- Perazine for schizophrenia. (2002) (0)
- Carbamazepine for schizophrenia and schizoaffective psychoses. (2000) (0)
- Contents of The American Journal of Psychiatry (2004) (0)
- Influence of polymorphism in the CYP1A2, the UGT1A4 and the POR gene on olanzapine serum concentrations and clinical outcome (2013) (0)
- Structured implementation of digital, systematically updated guideline recommendations for enhanced adherence in schizophrenia (SISYPHOS)—protocol of a cluster-randomized trial (2022) (0)
- Poster #217 EFFICACY AND ACCEPTABILITY OF BENZODIAZEPINE AUGMENTATION OF ANTIPSYCHOTICS IN SCHIZOPHRENIA AND SCHIZOPHRENIA-LIKE PSYCHOSES: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (2012) (0)
- Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE Study. (2023) (0)
- Title Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder : a systematic review and network meta-analysis (2019) (0)
- Comprar Physical Illness & Schizophrenia - A Review of the Evidence | Stefan Leucht | 9780521882644 | Cambridge University Press (2007) (0)
- Physical Illness and Schizophrenia: Discussion (2007) (0)
- MC4R rs489693 polymorphism influences antipsychotic-related weight gain (2013) (0)
- F214. PSYCHOLOGICAL INTERVENTIONS FOR POSITIVE SYMPTOMS IN SCHIZOPHRENIA: A NETWORK META-ANALYSIS (2018) (0)
- Relapse prevention in schizophrenia - Authors' reply. (2022) (0)
- Intramuscular haloperidol and olanzapine begin to reduce psychosis within 24 hours (2006) (0)
- Poster #S232 EFFICACY OF SECOND- VERSUS FIRST-GENERATION ANTIPSYCHOTIC DRUGS FOR TREATMENT-RESISTANT SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (2014) (0)
- Network meta-analysis of the efficacy and safety of antidepressants for acutely ill elderly patients with major depressive disorder (2018) (0)
- Carbamazepine for schizophrenia: A systematic review and meta-analysis (2000) (0)
- Negative symptoms, striatal dopamine, and model-free reward decision-making in schizophrenia. (2022) (0)
- Second-generation antipsychotics and seizures – a systematic review and meta-analysis of serious adverse events in randomized controlled trials (2023) (0)
- S145. CORTICO-THALAMIC DYSCONNECTIVITY LINKS WITH ABERRANT STRIATAL DOPAMINE IN SCHIZOPHRENIA A SIMULTANEOUS 18F-DOPA-PET/RESTING-STATE FMRI STUDY (2020) (0)
- The treatment of schizophrenia - the state of the evidence (2008) (0)
- Statement on the debate about second-generation antipsychotics (2010) (0)
- SA21. Network Analysis of the SANS: Analysis of 3 Randomized Clinical Trials of Predominant Negative Symptoms. (2017) (0)
- Books Received (2008) (0)
- P.441 Impact of CYP2C19 and CYP2D6 polymorphism on antidepressants and antipsychotics exposure; a meta-analysis (2020) (0)
- S47. ADD-ON SPIRONOLACTONE FOR THE TREATMENT OF SCHIZOPHRENIA (SPIRO TREAT) (2018) (0)
- University of Groningen The role of depression in the prediction of a "late" remission in first-episode psychosis (2021) (0)
- Antidepressants for central pain (2009) (0)
- Informing the development of a decision aid: Expectations and wishes from service users and psychiatrists towards a decision aid for antipsychotics in the inpatient setting (2023) (0)
- META-ANALYSIS ON RELAPSE PREVENTION WITH ANTIPSYCHOTIC DRUGS COMPARED TO PLACEBO IN SCHIZOPHRENIA (2012) (0)
- Delayed Onset of Drug Effects (2014) (0)
- Is there a differential efficacy of new generation antipsychotic drugs? (2005) (0)
- New generation versus conventional antipsychotics [3] (multiple letters) (2003) (0)
- CYP2C19*2 but not*17 Influence Amitriptyline and Citalopram Serum Concentrations: Intermediate Metabolizer Status may be of Clinical Relevance (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Stefan Leucht?
Stefan Leucht is affiliated with the following schools:
